contributing to the growth of the heart failure market are increasing incidence of cardiac disorders,
aging population, lack of exercise, diet containing high fat and salt content, stress, increasing alcohol
consumption, and smoking.
Major Players profiled in the Heart Failure Market report incorporate: Boston Scientific Corporation,
Pfizer, GlaxoSmithKline plc, Novartis International AG, Bristol-Myers Squibb Company, Merck Sharp &
Dohme.
Latest Industry News
1 Boston Scientific Europe announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe.
With this launch, the first and only diagnostic tool that enables proactive heart failure (HF) care is now
available for patients in select countries across Europe including Italy, Spain, UK, Germany, Austria and
Switzerland, with more to follow in the coming months. At present, heart failure affects more than 15
million people in Europe and accounts for approximately 3 million hospitalisations and numerous deaths
each year.1 The HeartLogic diagnostic provides continuous measurement of early worsening signs of
heart failure by combining data from sensors evaluating heart sounds, respiration rate and volume,
thoracic impedance, heart rate and activity. HeartLogic’s unique algorithm is built into the Resonate and
next generation Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and implantable cardiac
defibrillators (ICDs).
2 Novartis announced results of the landmark PIONEER-HF trial showing that in-hospital initiation of
Entresto tablets provided superior benefit compared to enalapril-a heart failure medication commonly
used-in patients with HFrEF who had been stabilized following admission for an acute decompensation
heart failure (ADHF) event. Patients on Entresto in PIONEER-HF had a 29% greater reduction in time-
averaged N-terminal pro-B-type natriuretic peptide (NT-proBNP) at weeks 4 and 8 (the primary
endpoint) compared to enalapril patients (95% CI: 0.63, 0.81; P<0.0001)[1]. Significant reductions in NT-
proBNP were observed in Entresto patients as early as 1 week after treatment initiation. NT-proBNP is
an established biomarker used to assess the severity and determine the prognosis of heart failure[4].
Notably, the superior NT-proBNP reduction with Entresto was consistent across diverse HFrEF patient
populations stabilized following admission for ADHF, including those newly diagnosed with HFrEF, those
not receiving an ACEi/ARB treatment and African Americans.
Purchase this report online with 50 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global Heart Failure Market Report 2019” @ https://www.businessindustryreports.com/buy-
now/162959/single .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Heart Failure in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation